[{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Undisclosed","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"Trk receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AC-0027838","moa":"TrkA receptor","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"TrkA receptor","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"ACD856","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AC-0027875","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AC-0027875","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ACD680","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ACD440","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ACD440","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ACD856","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"ACD440","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ACD137","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"},{"orgOrder":0,"company":"AlzeCure Pharma AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"ACD137","moa":"","graph1":"Musculoskeletal","graph2":"Preclinical","graph3":"AlzeCure Pharma AB","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"AlzeCure Pharma AB \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AlzeCure Pharma AB \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by AlzeCure Pharma AB
Details :
AlzeCure's ACD137 is a potent and selective negative allosteric modulator of TrkA, which is currently being evaluated for the treatment of osteoarthritis pain.
Details :
ACD137 is being developed within the TrkA-NAM project in AlzeCure's Painless platform. It is being evaluated in preclinical studies for the treatment of severe pain & osteoarthritis.
Details :
ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. It targets severe pain in conditions such as osteoarthritis.
Details :
ACD856 and other substances in the NeuroRestore platform stimulate several important signaling systems and signaling molecules in the brain such as BDNF and NGF. EPO has granted a patent covering Alzheimer'sdisease and other disorders with cognitive impa...
Details :
ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. It targets severe pain in conditions such as osteoarthritis.
Details :
ACD440 is a TRPV1 antagonist for the local treatment of patients with peripheral neuropathic pain. It targets severe pain in conditions such as osteoarthritis.
Details :
ACD680 (alzstatin) is a gamma-secretase modulator (GSM), which constitutes a promising class of small-molecule Aβ42-lowering anti-amyloidogenic substances for preventive and disease-modifying treatment of Alzheimer's disease.
Details :
The presentation includes new preclinical results with AlzeCure's compound AC-0027875, which is a new potent small molecule gamma-secretase modulator (GSM) and part of AlzeCure's research platform Alzstatin®.
Details :
AC-0027875 is a novel potent small molecule γ-secretase modulator and part of AlzeCure's research platform Alzstatin. γ-Secretase modulators, so called GSMs, represent a promising class of Aβ42-lowering anti-amyloidogenic compounds for treatment of Al...
Details :
A positive modulator of both NGF/TrkA- and BDNF/TrkB-mediated signaling, ACD856 has been shown in preclinical studies to improve cognition and memory and is poised for Phase 2 clinical trials, where it is being developed primarily for the treatment of Al...
Reset All
